What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Monopar Therapeutics MNPR Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers SquibbBMY

$199M+15.7%

Prime MedicinePRME

$8.55M+24.6%

Wave Life SciencesWVE

$8.33M+5.6%

Perspective TherapeuticsCATX

$1.07M+9.1%

Amylyx Pharmaceuticals, Inc.AMLX

$1.16M+9.5%

ArriVent BioPharma, Inc.AVBP

$99K-28.3%

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's operating lease liabilities (current)?: Monopar Therapeutics (MNPR) reported operating lease liabilities (current) of $98.86K in Q1 2026.
How has Monopar Therapeutics's operating lease liabilities (current) changed year-over-year?: Monopar Therapeutics's operating lease liabilities (current) increased by 1098.0% year-over-year, from $8.25K to $98.86K.
What does operating lease liabilities (current) mean?: The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.